Quote | Kiromic BioPharma Inc. (NASDAQ:KRBP)
Last: | $1.45 |
---|---|
Change Percent: | 0.0% |
Open: | $1.58 |
Close: | $1.45 |
High: | $1.58 |
Low: | $1.45 |
Volume: | 12,952 |
Last Trade Date Time: | 09/13/2023 03:00:00 am |
News | Kiromic BioPharma Inc. (NASDAQ:KRBP)
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...
Message Board Posts | Kiromic BioPharma Inc. (NASDAQ:KRBP)
Subject | By | Source | When |
---|---|---|---|
in the red now fun while it lasted | koolmc | investorshub | 04/17/2023 6:33:53 PM |
znewcar1: $KRBP hod6.96 PMH7.75 flushed | znewcar1 | investorshangout | 04/17/2023 3:36:14 PM |
Wild | Awl416 | investorshub | 04/17/2023 10:37:23 AM |
$KRBP...................................https://stockcharts.com/h-sc/ui?s=$KRBP&p= | glenn1919 | investorshub | 04/15/2023 7:15:44 PM |
There she goes | Awl416 | investorshub | 04/14/2023 8:34:21 PM |
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
NASDAQ Market:
Kiromic BioPharma Inc. Website:
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...
Scans of this first patient in the second cohort show 8.5% reduction in tumor size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable safety and tolerability, and early efficacy in the fourth patient enrolled in the Compa...